www.fdanews.com/articles/200760-emergex-partners-with-brazils-bio-manguinhos-to-develop-covid-19-vaccine
Emergex Partners with Brazil’s Bio-Manguinhos to Develop COVID-19 Vaccine
January 7, 2021
Emergex and Brazil’s Institute of Technology on Immunobiologicals (Bio-Manguinhos) have agreed to work together on “certain immunotherapeutic programs,” including a COVID-19 vaccine.
Emergex will support studies, including clinical trials, and will manufacture, market, promote and distribute certain vaccines within Brazil’s National Health Service, the UK company said.
The COVID-19 vaccine they will co-develop will use Emergex’s synthetic T-Cell vaccine technology. Financial details of the agreement were not disclosed.